Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q39615516)
Watch
English
Pembrolizumab (Keytruda)
scientific article published on 11 July 2016
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
5137544
retrieved
13 September 2017
review article
1 reference
stated in
Europe PubMed Central
title
Pembrolizumab (Keytruda)
(English)
1 reference
stated in
Europe PubMed Central
PMCID
5137544
retrieved
13 September 2017
main subject
pembrolizumab
1 reference
based on heuristic
inferred from title
author
T Yau
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
Joanne Chiu
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
Eric Tse
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
author name string
Gerry Kwok
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
Yok-Lam Kwong
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
publication date
11 July 2016
1 reference
stated in
Europe PubMed Central
PMCID
5137544
retrieved
13 September 2017
published in
Human Vaccines & Immunotherapeutics
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
volume
12
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
issue
11
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
page(s)
2777-2789
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
cites work
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Cancer statistics, 2016
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Novel immunotherapies in lymphoid malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Pembrolizumab for the treatment of non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Pembrolizumab versus Ipilimumab in Advanced Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Immune checkpoint blockade: a common denominator approach to cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Clinical blockade of PD1 and LAG3--potential mechanisms of action
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Improved overall survival in melanoma with combined dabrafenib and trametinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
The tumour microenvironment in B cell lymphomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Nivolumab plus ipilimumab in advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
T cell exhaustion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Final version of 2009 AJCC melanoma staging and classification
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-1 and its ligands in tolerance and immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Restoring function in exhausted CD8 T cells during chronic viral infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
14 September 2017
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
25 September 2017
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
17 June 2018
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
17 June 2018
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
17 June 2018
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
21 August 2018
Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
21 August 2018
The Genetic Evolution of Melanoma from Precursor Lesions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
21 August 2018
Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5137544
retrieved
21 August 2018
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27398650
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27398650
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27398650
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1080/21645515.2016.1199310
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
PMCID
5137544
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
PubMed ID
27398650
1 reference
stated in
Europe PubMed Central
PMCID
5137544
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27398650%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 June 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
